LillyDirect $299 Zepbound Vials: The Catch Nobody Mentions
Eli Lilly advertises Zepbound starting at $299/month. The actual 12-month cost when you factor in dose escalation and the 45-day refill rule? Closer to $4,700. Here's the math.
The Catch
The $299 price is only the starting dose (2.5mg) for month 1. Every Zepbound patient titrates up over 16–20 weeks. By month 4, you're paying $449/month, and the $50–150 discount on doses 7.5mg+ requires you to refill within 45 days of the previous delivery — miss that window and you pay full price. Actual 12-month cost for most patients: $4,600–$4,800.
On December 1, 2025, Eli Lilly announced a price cut on Zepbound single-dose vials through its direct-to-consumer platform, LillyDirect. The headline: $299/month. Consumer press reported it everywhere. Shares of Lilly moved. Patients filed to sign up.
What the headlines didn't say — and what Lilly's own press release buries — is that $299 is the 2.5mg starter dose only. Zepbound dose escalation is standardized. Here's the real schedule:
The Zepbound dose ladder (and what each dose actually costs)
| Week | Dose | LillyDirect Price | Notes |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg | $299/mo | Starter dose |
| Weeks 5–8 | 5 mg | $399/mo | First titration |
| Weeks 9–12 | 7.5 mg | $449/mo | 45-day refill rule kicks in |
| Weeks 13–16 | 10 mg | $449/mo | Maintenance candidate |
| Weeks 17–20+ | 12.5–15 mg | $449/mo | Maximum therapeutic dose |
Most patients will not stay on 2.5mg. That dose is a training-wheels dose designed to minimize nausea. Clinical weight loss happens at 10–15mg.
The 12-month math
Here's the realistic cost for a patient who titrates normally and stays on the medication for a full year:
| Month | Dose | Cost |
|---|---|---|
| Month 1 | 2.5 mg | $299 |
| Month 2 | 5 mg | $399 |
| Month 3 | 7.5 mg | $449 |
| Months 4–12 | 10 or 15 mg | $449 × 9 = $4,041 |
| 12-month total | $5,188 |
The advertised "$299/month" number accurately describes one month of your treatment. The other 11 cost $399–$449.
How this compares to Wegovy's flat pricing
Novo Nordisk's Wegovy costs $349/month at every dose. No titration pricing. No refill-window penalty. The 12-month cost for a Wegovy patient is $4,188 — or $2,988 if they lock in the 12-month subscription at $249/mo.
That's $1,000–$2,200 cheaper than LillyDirect Zepbound over a year. For the same active-ingredient class and a similar clinical outcome, Wegovy is now the cheaper brand-name path for most patients.
Zepbound still wins on efficacy
Here's where it gets complicated. Head-to-head trials show tirzepatide (Zepbound) produces higher average weight loss than semaglutide (Wegovy): roughly 20% vs. 15% of body weight over 72 weeks. If you're choosing between medications purely on effect size, Zepbound wins.
So the real question isn't "$299 vs. $349." It's: "Is ~$1,500 more per year worth the added 5% body weight loss?" For a 250-lb patient, that's an extra ~12 pounds over 18 months. Your answer depends on how much that matters to you.
The vial-vs-pen problem
Novo's Wegovy pricing applies to both pens and pills. You pick the format, pay $349 (or less on subscription), and that's that. Lilly's $299 is specifically a vial-only offer designed to compete with cheap compounded vials — because that's the format compounded pharmacies sell.
Compounded tirzepatide: the real competitor
The provider Zepbound at $299–449/mo is actually competing against is compounded tirzepatide, not Wegovy. Here's what that market looks like:
- Synergy Rx: compounded tirzepatide injectable + oral, bundled with semaglutide at $200/mo
- MEDVi: compounded tirzepatide, injectable + oral at $179/mo
- Sprout Health: compounded tirzepatide $299/mo (injection) or $299/mo (tablets)
- Care Bare Rx: compounded tirzepatide at $199/mo
Compounded tirzepatide at $179–299/mo is the direct competitor to Zepbound's $299–449 pricing. It's not FDA-approved as a finished compounded product, but it contains the same active ingredient and has been safely prescribed to hundreds of thousands of patients since 2023.
When the $299 price actually makes sense
LillyDirect Zepbound at $299 is the right call for:
- Trial-and-error patients. If you only want one month of Zepbound to test tolerability, $299 for the 2.5mg starter is a reasonable experiment.
- Microdosers. Some patients stay on 2.5–5mg long-term for lighter appetite suppression. If you don't titrate up, the $299–399 price holds.
- Insured patients with high deductibles. The Lilly savings program can drop insured patients to $25/mo — $299 is the uninsured backstop.
- Vial-comfortable users. If you don't mind drawing from vials, you skip the pen premium.
When to skip Zepbound and pick compounded
- You know you'll titrate up to 7.5mg+ (most patients do)
- You want month-to-month flexibility with no refill-window stress
- Your budget is hard-capped under $300/month
- You want a pen-style delivery (compounded pens exist at select providers)
Synergy Rx
Compounded tirzepatide — injectable + oral. Direct competitor to Zepbound at 55% less.
Check Synergy →Sesame Care (Brand)
Get a Zepbound prescription through a licensed provider, no LillyDirect dose-escalation trap.
Check Sesame →MEDVi
Compounded tirzepatide (injectable + oral). Budget-friendly alternative.
Check MEDVi →The bigger takeaway
The $299 Zepbound headline is real — but it's a hook, not a full-picture price. Lilly made a strategic choice to advertise the low starter dose rather than a flat annual cost like Novo did. Both approaches are valid marketing. Neither is wrong. But patients comparing "$299 Zepbound vs. $349 Wegovy" are not doing apples-to-apples math. Over 12 months, Wegovy is the cheaper brand-name option.
If you want tirzepatide specifically and don't have insurance, compounded tirzepatide at $179–299/mo from Synergy Rx, MEDVi, or Care Bare Rx will save you thousands annually over LillyDirect. That's still the budget play.